Journal of Pharmacological Sciences (Print Edition) 2007-11-01

Effects of azimilide on the muscarinic acetylcholine receptor-operated K+ current and experimental atrial fibrillation in guinea-pig hearts.

Atsushi Nishida, Yoshie Reien, Takehiko Ogura, Hiroko Uemura, Masaji Tamagawa, Hideo Yabana, Haruaki Nakaya

Index: J. Pharmacol. Sci. 105(3) , 229-39, (2007)

Full Text: HTML

Abstract

Effects of azimilide, a class III antiarrhythmic drug, on the acetylcholine (ACh) receptor-operated K+ current (I K.ACh) and the delayed rectifier K+ current (IK) were examined in guinea-pig atrial cells using patch-clamp techniques. Effects of azimilide on experimental atrial fibrillation (AF) were also examined in isolated guinea-pig hearts. In single atrial myocytes, azimilide inhibited both the rapid (IKr) and slow component of IK (IKs). Azimilide inhibited the I K.ACh induced by carbachol (CCh, 1 microM), adenosine (10 microM), and intracellular loading of GTPgammaS (100 microM) in a concentration-dependent manner. The IC50 values of azimilide for inhibiting the CCh-, adenosine-, and GTPgammaS-induced I K.ACh were 1.25, 29.1, and 20.9 microM, respectively, suggesting that azimilide inhibits I K.ACh mainly by blocking the muscarinic receptors. Azimilide concentration-dependently (0.3 - 10 microM) prolonged the action potential duration (APD) in the absence and presence of muscarinic stimulation. In isolated hearts, perfusion of CCh shortened the duration of the monophasic action potential (MAP) and effective refractory period (ERP) of the left atrium and lowered the atrial fibrillation threshold (AFT). Addition of azimilide inhibited the induction of AF by prolonging the duration of MAP and ERP. The I K.ACh inhibition by azimilide may at least in part contribute to the effectiveness to prevent parasympathetic-type AF.


Related Compounds

  • Azimilide (Dihydr...

Related Articles:

Azimilide dihydrochloride: a new class III anti-arrhythmic agent.

2000-11-01

[Expert Opin. Investig. Drugs 9(11) , 2705-15, (2000)]

Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro.

2006-07-01

[Europace 8(7) , 549-57, (2006)]

Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias.

2008-02-01

[J. Cardiovasc. Electrophysiol. 19(2) , 172-7, (2008)]

Role of drug therapy for sustained ventricular tachyarrhythmias.

2008-08-01

[Cardiol. Clin. 26(3) , 405-18, vi, (2008)]

Inhibitory effect of azimilide on Na+/Ca2+ exchange current in guinea-pig cardiac myocytes.

2010-01-01

[J. Pharmacol. Sci. 114(1) , 111-4, (2010)]

More Articles...